Avalo Therapeutics Inc (AVTX)

Currency in USD
18.840
+1.550(+8.96%)
Closed·
19.000+0.160(+0.85%)
·
Advertisement
AVTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.27018.965
52 wk Range
4.61024.270
Key Statistics
Prev. Close
17.29
Open
17.45
Day's Range
17.27-18.965
52 wk Range
4.61-24.27
Volume
1.82M
Average Volume (3m)
1.95M
1-Year Change
279.8387%
Book Value / Share
3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AVTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
45.250
Upside
+140.18%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Avalo Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 45.250
(+140.18% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BofA Securities
Buy35.00+85.77%-New Coverage12/06/2026
H.C. Wainwright
Buy35.00+85.77%40.00Maintain14/05/2026
Mizuho
Buy45.00+138.85%39.00Maintain14/05/2026
Citizens
Buy55.00+191.93%62.00Maintain14/05/2026
Piper Sandler
Buy60.00+218.47%48.00Maintain11/05/2026

Earnings

Latest Release
13/05/2026
EPS / Forecast
-0.98 / -1.76
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare AVTX to Peers and Sector

Metrics to compare
AVTX
Peers
Sector
Relationship
P/E Ratio
−11.7x−3.6x−0.4x
PEG Ratio
−0.16−0.050.00
Price/Book
14.5x2.5x2.6x
Price / LTM Sales
16,785.3x87.2x3.0x
Upside (Analyst Target)
130.9%236.2%50.7%
Fair Value Upside
Unlock−0.1%6.5%Unlock

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
5.93M11.27%102.47M
Other Institutional Investors
52.03M88.73%899.58M
Public Companies & Retail Investors
0.000.00%0.00
Total
57.96M100.00%1B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC6.07%3,188,40155,127
Deep Track Biotechnology Master Fund, Ltd5.81%3,055,02752,821

People Also Watch

19.140
MRAM
-14.32%
4.520
MNKD
+11.60%
7.74
AURA
+15.01%
5.9100
MNTS
-9.08%
14.980
SLS
+12.89%

FAQ

What Is the Avalo Therapeutics (NASDAQ: AVTX) Share Price Today?

The Avalo Therapeutics stock price today is 18.840 USD.

What Stock Exchange Does Avalo Therapeutics (AVTX) Trade On?

Avalo Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Avalo Therapeutics?

The stock symbol (also called a 'ticker') for Avalo Therapeutics is "AVTX."

What Is the Current Avalo Therapeutics Market Capitalisation?

As of today, Avalo Therapeutics (NASDAQ: AVTX) market cap is 990.340M USD.

What Is Avalo Therapeutics's (AVTX) Earnings Per Share (TTM)?

The Avalo Therapeutics EPS is currently -5.364 (Trailing Twelve Months).

When Is the Next Avalo Therapeutics Earnings Date?

Avalo Therapeutics's next earnings report will be released on 30/07/2026.

Is AVTX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Avalo Therapeutics moving averages and other technical indicators, the daily buy/sell signal for AVTX stock is Strong Buy.

How Many Times Has Avalo Therapeutics Stock Split?

Avalo Therapeutics has split 2 times. (See the AVTX stock split history page for full effective split date and price information.)

How Many Employees Does Avalo Therapeutics Have?

Avalo Therapeutics has 33 employees, based on their latest Companies House report.

What is the current trading status of Avalo Therapeutics (NASDAQ: AVTX)?

As of 03/07/2026, Avalo Therapeutics (AVTX) is trading at a share price of 18.840 USD, with a previous close of 17.290 USD. The stock has fluctuated within a day range of 17.270 USD to 18.965 USD, while its 52-week range spans from 4.610 USD to 24.270 USD.

What Is Avalo Therapeutics (AVTX) Price Target According to Analysts?

The average 12-month price target for Avalo Therapeutics is 45.250 USD, with a high estimate of 60 USD and a low estimate of 34 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +140.18% Upside potential.

What Is the AVTX After Hours Price?

AVTX's last after hours stock price is 19.000 USD, the stock has decreased by 0.160, or 0.850%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.